----

----

| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|-----------------------------------------------------------------------------------------|

|  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------|------------------------------------------------------------------------------------------|

|                                                          |   |                                |
|---------------------------------------------------------------|--------|-------------------------------------|
| DELAWARE                                                      |   | 93-0987903                          |
| (STATE OR OTHER JURISDICTION OFINCORPORATION OR ORGANIZATION) |   | (I.R.S. EMPLOYERIDENTIFICATION NO.) |

| Large accelerated filer |   |  ̈                                                          |    | Accelerated filer              |   |  ̈ |
|-----------------------------------|--------|-----------------------------------------------------------------|--------------|-------------------------------------|--------|--------|
|                              |   |                                                            |         |
| Non-accelerated filer             |   |  ̈  (Do not check if a smaller reporting company) |    | Smaller reporting company |   | x      |

----

----

----

| Exhibit No. |                                                                                                                                   | Description |   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------|-------------|--------|
|        |                                                                                                                                   |        |   |
| 10.1        | Non-Employee Director Compensation Policy                                                                                              |
|        |                                                                                                                                   |
| 10.2        | Standard Industrial Net Lease, dated as of May 23, 2008, by and between MabVax Therapeutics, Inc. and Sorrento Square             |
|        |                                                                                                                                   |
| 10.3        | First Amendment to that Standard Industrial Net Lease, dated May 6, 2010, by and between MabVax Therapeutics, Inc. and Sorrento Square |

| 10.4   | Second Amendment to that Standard Industrial Net Lease, dated August 1, 2012, by and between the Company and Sorrento Square                           |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                   |   |
| 10.5   | Employment Agreement, dated July 21, 2014, by and between MabVax Therapeutics, Inc. and Paul Maffuid, Ph.D.                                       |
|   |                                                                                                                                                   |   |
| 10.6   | Development and Manufacturing Services Agreement, dated April 15, 2014, by and between MabVax Therapeutics, Inc. and Gallus BioPharmaceuticals NJ, LLC |

| 10.7   | Exclusive License Agreement for “Polyvalent Conjugate Vaccines for Cancer” (SK#14491), dated as of June 30, 2008, by and between MabVax Therapeutics, Inc. and Sloan-Kettering Institute for Cancer Research |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                          |   |
| 10.8   | Research and License Agreement, dated as of April 7, 2008, by and between MabVax Therapeutics, Inc. and Sloan-Kettering Institute for Cancer Research                                                                    |
|   |                                                                                                                                                                                                                          |   |
| 10.9   | Exclusive License to Unimolecular Antibodies, dated October 13, 2011, by and between MabVax Therapeutics, Inc. and Sloan-Kettering Institute for Cancer Research                                                              |
|   |                                                                                                                                                                                                                          |   |
| 10.10  | Option Agreement, dated August 29, 2014, by and between MabVax Therapeutics, Inc. and Juno Therapeutics, Inc.                                                                                                                 |

| 10.11                         | SBIR Contract from National Cancer Institute                                                                                          |                                                              |   |   |   |   |   |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|--------|--------|--------|--------|--------|
|                          |                                                                                                                                  |                                                                   |   |   |
| 31.1                          | Certification of Principal Executive Officer required by Section 302 of the Sarbanes-Oxley Act of 2002                           |
|                          |                                                                                                                                  |                                                                   |   |   |   |   |   |   |
| 31.2                          | Certification of Principal Financial Officer required by Section 302 of the Sarbanes-Oxley Act of 2002                           |
|                          |                                                                                                                                  |                                                                   |   |   |   |   |   |   |
| 32                            | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|                          |                                                                                                                                  |                                                                   |   |   |   |   |   |   |
|      99.1 |                                                                                                                                  | MabVax Therapeutics, Inc. Granted and Pending Patents and Applications |   |   |   |   |   |   |

----

|                  |   |   |   |                               |   |                                                                                                               |
|-----------------------|--------|--------|--------|------------------------------------|--------|--------------------------------------------------------------------------------------------------------------------|
| Date: August 12, 2015 |   |   |   | MABVAX THERAPEUTICS HOLDINGS, INC. |
|                  |   |   |   |
|                  |   |   |   | By:                                |   | /s/ J. David Hansen                                                                                                |
|                  |   |   |   |                               |   | J. David Hansen                                                                                                    |
|                  |   |   |   |                               |   | President and Chief Executive Officer (Principal Executive Officer authorized to sign on behalf of the registrant) |

|   |   |   |   | By:    |   | /s/ Gregory P. Hanson                                                                                               |
|--------|--------|--------|--------|--------|--------|---------------------------------------------------------------------------------------------------------------------|
|   |   |   |   |   |   | Gregory P. Hanson                                                                                                   |
|   |   |   |   |   |   | Chief Financial Officer (Principal Financial and Accounting Officer authorized to sign on behalf of the registrant) |